Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Endoscopic radiofrequency ablation excels for pancreatic tumors

Key clinical point: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is an attractive emerging option for treatment of patients with unresectable pancreatic tumors.

Major finding: EUS-RFA had an 84.5% clinical success rate and reassuring safety profile for treatment of unresectable malignant and benign pancreatic tumors.

Study details: This was a meta-analysis of 13 published studies of EUS-RFA therapy applied to 127 patients with unresectable pancreatic tumors.

Disclosures: The presenter reported no financial conflicts regarding his study, conducted free of commercial support.

Citation:

Dhaliwal A. ACG 2019 Abstract 30.